Cargando…

Characteristics of Prior Authorization Policies for New Drugs in Medicare Part D

This cross-sectional study examines the characteristics of prior authorization policies for new drugs in Medicare Part D to understand whether they are consistent with US Food and Drug Administration indications.

Detalles Bibliográficos
Autores principales:	Naci, Huseyin, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R., Kesselheim, Aaron S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958521/ https://www.ncbi.nlm.nih.gov/pubmed/36826829 http://dx.doi.org/10.1001/jamahealthforum.2022.5610

Ejemplares similares

Coverage of New Drugs in Medicare Part D
por: NACI, HUSEYIN, et al.
Publicado: (2022)

Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B
por: Schwartz, Aaron L., et al.
Publicado: (2021)

Medicare Spending on Drugs With Accelerated Approval, 2015-2019
por: Rome, Benjamin N., et al.
Publicado: (2021)

Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Evaluation of Prior Authorization in Medicare Nonemergent Ambulance Transport
por: Contreary, Kara, et al.
Publicado: (2022)

Medicare Part D on the Front Line
por: Collins, Andrew
Publicado: (2006)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysis
por: Li, David G, et al.
Publicado: (2019)

The Challenge of Medicare Part D for Community Pharmacies
por: Stone, Devin
Publicado: (2009)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries
por: Mark, Tami L., et al.
Publicado: (2020)

Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population
por: Ferries, Erin, et al.
Publicado: (2021)

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
por: Dean, Emma Boswell, et al.
Publicado: (2021)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Medicare Part D Coverage Gap Discount Program Beginning in 2011
por: Cahill, Judith A.
Publicado: (2010)

Analysis of Prescriptions Dispensed After Death and Associated Medicare Spending Following Reimbursement Policy Changes in Medicare
por: Vouri, Scott M., et al.
Publicado: (2023)

What Are Prior Authorization and the Formulary Exception Process?
por: Curtiss, Frederic R.
Publicado: (2005)

Prescriptions by Mail Improve Access and Affordability to Medications for Medicare Part D Beneficiaries
por: Frazee, Sharon Glave, et al.
Publicado: (2014)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D
por: Trish, Erin, et al.
Publicado: (2021)

Concordance Between Electronic Health Record Data and Medicare Part D Claims Data for Oral Anticancer Drug Use
por: Sharma, Manvi, et al.
Publicado: (2020)

Medicare Quality Improvement Organizations' Ambulatory Drug Therapy Improvement Activities and Partnerships With Medicare Part D Prescription Drug Plans and Medicare Advantage Plans
por: Schulke, David G., et al.
Publicado: (2007)

Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019
por: Hussaini, S. M. Qasim, et al.
Publicado: (2022)

Rosiglitazone Prior Authorization Safety Policy: A Cohort Study
por: Starner, Catherine I., et al.
Publicado: (2012)

The influence of Medicare Part D on the list pricing of brand drugs
por: Ippolito, Benedic N., et al.
Publicado: (2023)

Characteristics of Terminated Medicare Advantage Contracts, 2011 to 2020
por: Meyers, David J., et al.
Publicado: (2022)

Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage
por: Kesselheim, Aaron S., et al.
Publicado: (2017)

Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization
por: Hechter, Rulin C., et al.
Publicado: (2017)

Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care
por: Abraham, Amanda J., et al.
Publicado: (2022)

Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
por: Tseng, Chien-Wen, et al.
Publicado: (2020)

Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023)

Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Risk factors of self-reported adverse drug events among Medicare enrollees before and after Medicare Part D
por: Shiyanbola, Olayinka O., et al.
Publicado: (2009)

History Bias, Study Design, and the Unfulfilled Promise of Pay-for-Performance Policies in Health Care
por: Naci, Huseyin, et al.
Publicado: (2016)

Evaluation of Trends in Oncology Drug Spending in Medicare, 2016 to 2020
por: Kyle, Michael Anne, et al.
Publicado: (2022)

Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review
por: Wang, Bo, et al.
Publicado: (2015)

Therapeutic Value of Drugs Frequently Marketed Using Direct-to-Consumer Television Advertising, 2015 to 2021
por: Patel, Neeraj G., et al.
Publicado: (2023)

Medicare Disease Management in Policy Context
por: Linden, Ariel, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2f42o36lc8k448dgcedidkro0h